Steering Committee

professionals covering all aspects of product and company development

Our Steering Committee is formed by professionals endowed with very deep experience in life sciences, acquired within pharma, biotech and service companies.

The main responsibility of the Steering Committee is to assist the Managing Director of Rare Partners in identifying the best development strategy and selecting the best CROs, service companies and consultants for each specific project.

Germano Carganico, Chairman of the Steering Committee

Marco Prosdocimi, Managing Director

Anita Falezza

Fabrizio Minoja

Paolo Baroldi

Germano Carganico

Germano CarganicoGermano, graduated in Chemistry from Milan University in 1977, has a very long experience in R&D, regulatory affairs and company management, gained in pharmaceutical and biotech companies, such as Farmitalia Carlo Erba, Menarini, Axxam and MolMed.

He successfully managed the international registration of several new pharmaceutical products and has been founding partner of two leading consulting companies in the field of life sciences, namely Pharma Quality Europe and Regulatory Pharma Net.
Germano served as General Manager of Toscana Life Sciences foundation from 2005 to 2010 and has taught Business Development at the University of Siena in the same years. From 2011 to 2017 he worked for MolMed, where he held for five years the position of General Manager, R&D and Operations, and more recently that of Executive Director, Strategic Affairs.

Since August 2017 he is full time dedicated to Rare Partners, where is founding Partner and Chairman of the Steering Committee.

return to list

Marco Prosdocimi

Marco Prosdocimi - RP Managing DirectorMarco is Managing Director of Rare Partners since its foundation in March 2010. He collaborates as a consultant with Pharmaceutical Companies, with Investment Funds and with Research Organizations since 1996, focusing his activity in the areas of Research & Development.

Prior to this he rose to Research & Development Director at Fidia Research Laboratories during a 15-year career (1981-1996) with the company. Marco has more than 35 years of experience in R&D, gained in Academic Institutions (University of Padova and Thomas Jefferson University) and in companies, including CM&D Pharma, PharmEste and Angelini Ricerche.

He has been member of the scientific board of several biotech companies and collaborates with public and private institutions for the review of scientific projects and business plans. Marco is author of more than 120 papers, 200 abstracts and several patents, on cardiovascular and autonomic pharmacology, both at preclinical and clinical level.

Marco holds a degree in Pharmacy from the University of Padova.

return to list

Anita Falezza

Anita FalezzaAnita founded Regulatory Pharma Net s.r.l. in 1999, after having held various positions in the pharmaceutical industry since 1989, such as Regulatory Affairs Director, International Regulatory Affairs Manager, Study Director.

Her activities are focused in consulting and strategic coordination of Drug Development and Regulatory Affairs projects in Europe. Anita has directly participated in Price and Reimbursement procedures, Scientific Advice, Paediatric Investigation Plans, Orphan Drug Designations, Drug Development Plans, Centralised, Decentralised, and Mutual Recognition Procedures and Due Diligences, being in continuous contact with national and international regulatory authorities.
She has remarkable experience in Innovative Products, Anticancer Products, Biological and Biotechnological Products, and Advanced Therapies.
Anita holds a degree in Biological Sciences from the University of Pisa.

return to list

Fabrizio Minoja

Fabrizio MinojaFabrizio is partner at Bianchetti Bracco Minoja (BBM), a patent attorney’s firm representing national and international companies and research institutes, active in the pharmaceutical and biotechnological field. He qualified as European Patent Attorney in 1986.

Fabrizio has been appointed official expert of the Court of Milan and Turin in validity and infringement proceedings and has lectured at the University of Milan and at the Basic European Patent Law courses, Centre d'Etudes Internationales de la Propriété Industrielle (CEIPI), Robert Schumann University, in Strasburg.
Fabrizio graduated in Chemistry at the University of Milan.

return to list


Paolo Baroldi

Paolo BaroldiPaolo Baroldi, MD, PhD, currently is Chief Medical Officer (CMO) of Bloomscience, a biotech company focused on microbiome (San Diego, CA). From 2006 to 2009, and from 2013 to 2017, served as Senior Vice President and Chief Medical Officer at Vanda Pharmaceuticals. (Washington, DC).
In 2012-13, he was CEO of Galileo Research (Pisa), a spin-off biotech company of Abiogen Holding, focused on ovarian cancer immunotherapy.

From 2003 to 2006, Paolo served as Vice President of Corporate Drug development and Chairman of the R&D Board at Chiesi Farmaceutici SpA. From 1998 to 2002 he was Global Head of Clinical Pharmacology at Novartis Pharma, responsible for all early development studies across eight different therapeutic areas.

Paolo holds degrees in Medicine and Surgery (Universitas Studiorum Milan), Philosophy and History (Universitas Studiorum Milan), a PhD in Clinical Pharmacology (Universitas Studiorum Milan) and an Executive MBA from Harvard University.

Paolo held a contract professor position at Johns Hopkins University until 2014.

return to list


Chi siamo


Cosa facciamo